Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

Minoia C.; Pisapia G.; Palazzo G.; Ingrosso C.; Buonanno M.; Spinosa C.; Prudenzano A.; Pricolo G.; Mazza P.

首页> 外文期刊>Bone marrow transplantation >Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

【24h】

Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

机译：新药与自体造血干细胞移植对65岁或65岁以上多发性骨髓瘤患者的影响：回顾性单一机构分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2015年第11期|共1页
作者
Minoia C.; Pisapia G.; Palazzo G.; Ingrosso C.; Buonanno M.; Spinosa C.; Prudenzano A.; Pricolo G.; Mazza P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis [J] . Minoia C., Pisapia G., Palazzo G., Bone marrow transplantation . 2015,第11期

机译：新药与自体造血干细胞移植对65岁或65岁以上多发性骨髓瘤患者的影响：回顾性单一机构分析
2. Efficacy and safety of autologous stem cell transplantation in patients aged >= 65 years with multiple myeloma in the era of novel agents [J] . Mizuno Shohei, Kawamura Koji, Hanamura Ichiro, Bone marrow transplantation . 2019,第10期

机译：在新型剂时代患者患者= 65岁患者自体干细胞移植的疗效和安全性
3. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation [J] . OzakiS., HaradaT., SaitohT., Acta Haematologica . 2014,第2期

机译：新药和自体干细胞移植时代65-70岁的多发性骨髓瘤患者的生存
4. HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDM/SCT) FOR TREATMENT OF AL AMYLOIDOSIS: TEN YEAR SINGLE INSTITUTIONAL EXPERIENCE [C] . D. C. Setdin, V. Sanchorawala, K. Malek, International Symposium on Amyloidosis . 2005

机译：高剂量素母蛋白和自体干细胞移植（HDM / SCT）用于治疗Al淀粉样症：十年单一制度经验
5. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
6. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials [O] . Minjie Gao, Guang Yang, Ying Han, 2015

机译：多发性骨髓瘤自体造血干细胞移植后单剂硼替佐米或基于硼替佐米的方案作为巩固治疗：随机对照试验的荟萃分析
7. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis [O] . C Minoia, G Pisapia, G Palazzo, 2015

机译：新型剂对65岁或以上的多发性骨髓瘤患者的自体造血干细胞移植的影响：回顾性单一制度分析

Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

著录项

相似文献

相关主题

期刊订阅